ProCE Banner Activity

Phase II Trial of Niraparib ± Dostarlimab in Patients With Recurrent Endometrial Carcinoma

Slideset Download
Conference Coverage

Niraparib plus dostarlimab yields a clinical benefit rate of 31.8% vs 20.0% with monotherapy in patients with recurrent EC enriched for platinum resistant disease.

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme